Fig. 4From: Impact of erenumab on acute medication usage and health care resource utilization among migraine patients: a US claims database studyAcute medication use – proportion of patientsa in the 183 days before and after erenumab initiation. aNote that the results for ergots are not included due to insufficient data. The McNemar test was performed. NSAID, Non-steroidal anti-inflammatory drugBack to article page